Recent Events & Catalysts
Replimune Group, Inc. (REPL) — real, dated facts. Not a claim about what caused any single day's price move.
Committee Signals
Proprietary signals generated by the Innellis AI committee — score changes, rating shifts, and analyst disagreements.
No committee signals recorded yet.
News
Replimune Prices ~$150M Underwritten Offering Of 9,701,490 Shares And Warrants At $12.06 Per Unit
Benzinga · 1d ago
Wedbush Upgrades Replimune Group to Outperform, Raises Price Target to $19
Benzinga · 4d ago
Replimune Group, Inc. (REPL) Shareholder/Analyst Call Transcript
SeekingAlpha · 4d ago
Two Rejections, Messy Process: Replimune Finally Secures FDA Approval for Skin Cancer Treatment
Benzinga · 4d ago
Replimune Group, Inc. (REPL) Shareholder/Analyst Call - Slideshow
SeekingAlpha · 4d ago
Replimune Receives FDA Accelerated Approval For TUDRIQEVTM In Combination With Nivolumab For Treatment Of Adults With Unresectable Advanced Cutaneous Melanoma
Benzinga · 5d ago
Stock Picks From Seeking Alpha's July 2026 New Analysts
SeekingAlpha · 5d ago
This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Benzinga · 7d ago
SEC Filings (90 days)
Other events, Financial statements and exhibits
Filed 2026-08-11 · 0d ago
Other events, Financial statements and exhibits
Filed 2026-08-10 · 1d ago
Other events, Financial statements and exhibits
Filed 2026-08-07 · 4d ago
Other events, Financial statements and exhibits
Filed 2026-07-31 · 11d ago
Regulation FD disclosure, Financial statements and exhibits
Filed 2026-07-30 · 12d ago
Earnings
No recent earnings data available.
Latest Analyst Action
No recent analyst actions available.